June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Age-related macular degeneration (AMD), cardiovascular disease and stroke
Author Affiliations & Notes
  • Robert Thomson
    The University of Texas Health Science Center at Houston John P and Katherine G McGovern Medical School, Houston, Texas, United States
  • Joshua Chazaro
    Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, United States
  • Oscar Otero-Marquez
    New York Eye and Ear Infirmary of Mount Sinai Ophthalmology, New York, New York, United States
  • Gerardo Ledesma-Gil
    New York Eye and Ear Infirmary of Mount Sinai Ophthalmology, New York, New York, United States
    Vitreous Retina Macula Consultants of New York, New York, New York, United States
  • Yuehong Tong
    New York Eye and Ear Infirmary of Mount Sinai Ophthalmology, New York, New York, United States
  • Arielle Coughlin
    Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Zachary R. Teibel
    Hackensack University Medical Center, Hackensack, New Jersey, United States
  • Katy Tai
    New York Eye and Ear Infirmary of Mount Sinai Ophthalmology, New York, New York, United States
  • Harriet Lloyd
    New York Eye and Ear Infirmary of Mount Sinai Ophthalmology, New York, New York, United States
  • Richard B Rosen
    New York Eye and Ear Infirmary of Mount Sinai Ophthalmology, New York, New York, United States
    Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Lawrence Yannuzzi
    Vitreous Retina Macula Consultants of New York, New York, New York, United States
  • K Bailey Freund
    Vitreous Retina Macula Consultants of New York, New York, New York, United States
  • R. Theodore Smith
    New York Eye and Ear Infirmary of Mount Sinai Ophthalmology, New York, New York, United States
    Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Footnotes
    Commercial Relationships   Robert Thomson None; Joshua Chazaro None; Oscar Otero-Marquez None; Gerardo Ledesma-Gil None; Yuehong Tong None; Arielle Coughlin None; Zachary Teibel None; Katy Tai None; Harriet Lloyd None; Richard Rosen OptoVue, Boehringer-Ingelheim, Astellas, Genentech-Roche, NanoRetina, OD-OS, Regeneron, Bayer, Diopsys, Teva, Code C (Consultant/Contractor), Opticology, Guardion, CellView, Code I (Personal Financial Interest); Lawrence Yannuzzi None; K Bailey Freund Regeneron, Allergan, Zeiss, Bayer, Heidelberg Engineering, Novartis, Code C (Consultant/Contractor), Genentech/Roche, Code F (Financial Support); R. Theodore Smith Ora Technologies, Code C (Consultant/Contractor)
  • Footnotes
    Support  Regeneron Pharmaceuticals Investigator-Initiated Study, Research to Prevent Blindness Challenge Grant, Macula Foundation, Bayer-Global Ophthalmology Awards, International Council of Ophthalmology-Alcon Fellowship
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 3526. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Robert Thomson, Joshua Chazaro, Oscar Otero-Marquez, Gerardo Ledesma-Gil, Yuehong Tong, Arielle Coughlin, Zachary R. Teibel, Katy Tai, Harriet Lloyd, Richard B Rosen, Lawrence Yannuzzi, K Bailey Freund, R. Theodore Smith; Age-related macular degeneration (AMD), cardiovascular disease and stroke. Invest. Ophthalmol. Vis. Sci. 2022;63(7):3526.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The relationship between age-related macular degeneration (AMD), cardiovascular disease (CVD) and stroke has been long sought, with decades of inconsistent results. We demonstrate new, specific strong associations by first separating AMD into its two major intermediate phenotypes, soft drusen (SD) and subretinal drusenoid deposits (SDD), and comparing their associations with certain common high risk vascular diseases.

Methods : Two hundred AMD patients, ages 51 to 100, 121 females were recruited. Retinal imaging, health history questionnaires, and lipid profiles were obtained. Patients were assigned by volume spectral-domain optical coherence tomography (SD-OCT) into two groups, SDD (with or without SD) and SD (SD only). Fundus autofluorescence (AF) and near-infrared reflectance (NIR) imaging were used to confirm the presence of SDD. Self-reported health history questionnaires further classified patients into those with and without these high risk vascular disorders (HRV): 1) cardiac valve defect; 2) cardiac pump defect (myocardial infarction, congestive heart failure, etc); 3) carotid stroke or transient ischemic attack (TIA) with carotid stenosis. Chi-square testing was used for categorical variables. ‘Waikato 222 Environment for Knowledge Analysis (WEKA) Version 3.8.5’ was used to build a multivariate risk model for presence of HRV as a function of SDD status and other covariates.

Results : The prevalence of HRV was 41.24% (40/97) and 6.80% (7/103) in the SDD and SD groups respectively (p =0.000000009). Differences in the prevalence of HRV sub-types in these groups were also significant: valve defects 14/97 in SDD vs. 3/103 in SD (p = 0.0035), pump defects 16/97 vs. 3/103 (p = 0.0011), stroke/TIA 10/97 vs.1/103 (p = 0.0038). A serum HDL < 62 mg/dL was a strong predictor in our total AMD cohort of HRV (p = 0.0046). Data modeling showed that the joint presence of SDD and an HDL<62 predicted the presence of HRV with an accuracy of 85%, 95% CI, 77.5 %-90.7 %.

Conclusions : HRV were significantly more prevalent in subjects with SDD than those with SD only. This suggests that SDD specifically are a biomarker of these life-threatening systemic vasculopathies, all of which are likely to compromise ocular perfusion. This in turn suggests a direct vascular mechanism for SDD that merits investigation. Risk modeling shows a potential for saving lives by detecting occult HRV with non-invasive SD-OCT imaging and serum risk factors.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×